Brawn Biotech Peer Comparison

BSE: 530207

₹22.80

₹1.04 (4.78%)

As on 18-Sep-2026IST

Market cap

₹7 Cr

Revenue (TTM)

₹17 Cr

P/E Ratio

8

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	7	20,887	19,967	18,310	18,305
Revenue (₹ Cr)	17	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	0.86	678.07	273.51	666.92	735.15
Net Margin (%)	4.83	28.10	16.19	20.60	26.88
RoE (%)	21.33	19.73	11.15	18.75	19.16
Price to Earnings	7.97	31.39	67.16	28.44	24.90
Price-To-Book	1.52	5.69	7.43	4.54	4.15

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	17.26	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	17.76	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	17.72	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	-0.46	796.58	478.55	1,139.61	941.63
Depreciation	0.12	78.10	126.01	281.06	57.58
EBIT	-0.58	718.48	352.55	858.55	884.05
Interest	0.00	0.88	52.11	190.64	7.69
Other Income	0.50	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	-0.08	843.56	319.96	658.12	992.82
Provision for Tax	-0.94	165.49	46.45	-8.80	257.67
Profit after Tax	0.86	678.07	273.51	666.92	735.15

Liabilities (₹ Cr)

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	4.34	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	1.35	28.74	266.35	1,392.75	91.50
Current Liabilities	15.17	385.94	848.06	2,077.10	627.48
Total Liabilities	20.49	3,207.85	3,310.68	6,865.52	4,911.11

Assets (₹ Cr)

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	1.82	1,291.22	2,525.44	5,617.77	770.28
Current Assets	17.12	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	20.49	3,207.85	3,310.68	6,865.52	4,911.11
Total Debt*	0.00	0.55	586.37	2,421.66	2.50
Net Current Assets	1.95	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	--	0.64	76.22	51.96	363.79

Cashflow (₹ Cr)

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	0.05	432.37	132.27	1,065.01	659.75
Cash Flow from Investing Activities	-0.24	-334.73	-199.13	-79.97	-71.34
Cash from Financing Activities	0.00	-38.32	62.65	-881.32	-205.34
Net Cash Inflow / Outflow	-0.20	59.32	-4.21	103.72	383.07

Ratios

Profitability Ratios

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	-42.59	26.22	6.95	13.59	26.21
ROE (%)	21.33	19.73	11.15	18.75	19.16
ROA (%)	4.15	18.69	7.80	9.26	14.95
EBIT Margin (%)	-3.35	31.41	20.95	26.58	34.40
Net Margin (%)	4.83	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	-7.77	15.01	27.91	9.59	10.69
EBIT Growth (%)	-358.48	18.45	58.32	16.84	24.14
Net Profit Growth (%)	12.30	19.61	149.56	62.68	-9.09
EPS Growth (%)	12.30	17.73	-3.57	67.41	14.40
Book Value Growth (%)	-33.62	23.77	30.63	10.19	17.30

Valuation Ratios

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	7.97	31.39	71.24	27.75	23.73
Price / Book Value	1.52	5.69	7.43	4.54	4.15
Dividend Yield (%)	0.00	0.29	0.06	0.00	1.87
EV/EBITDA	-14.50	24.96	43.00	18.03	16.14
Market Cap (₹ Cr)	4.88	15,219.80	6,484.12	19,292.77	18,318.10

Solvency Ratios

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.00	0.00	0.07	0.24	0.00
Short term debt to equity ratio	--	0.00	0.13	0.14	0.00
Current Ratio	1.13	6.70	1.31	0.74	6.06
Quick Ratio	0.47	5.59	0.88	0.53	5.31
Interest Coverage	-19.50	959.59	7.14	4.45	130.11

Operating Efficiency Ratios

	Brawn Biotech	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	20.56	36.10	30.84	21.07	7.07
Asset Turnover	0.83	0.63	0.48	0.45	0.52
Receivable days	98.89	110.70	118.15	54.06	29.10
Inventory Days	223.41	65.86	98.29	32.16	69.53
Payable days	212.83	105.88	128.16	140.91	76.77
Cash Conversion Cycle	109.48	70.68	88.28	-54.69	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly